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Mitochondrial and inflammatory changes in sporadic inclusion body myositis
Aims: Sporadic inclusion body myositis (sIBM) is the most
common late onset muscle disease causing progressive
weakness. In light of the lack of effective treatment, we
investigated potential causes underlying muscle wasting.
We hypothesized that accumulation of mitochondrial res-
piratory deficiency in muscle fibres may lead to fibre
atrophy and degeneration, contributing to muscle mass
reduction. Methods: Histochemical and immunohisto-
chemical analyses were performed on muscle biopsies
from 16 sIBM patients to detect activity of mitochondrial
enzymes and expression of mitochondrial respiratory
chain proteins along with inflammatory markers respec-
tively. Mitochondrial DNA mutations were assessed in
single muscle fibres using real-time PCR. Results: We iden-
tified respiratory-deficient fibres at different stages of
mitochondrial dysfunction, with downregulated expres-
sion of complex I of mitochondrial respiratory chain being
the initial feature. We detected mitochondrial DNA rear-
rangements in the majority of individual respiratory-
deficient muscle fibres. There was a strong correlation
between number of T lymphocytes and macrophages
residing in muscle tissue and the abundance of
respiratory-deficient fibres. Moreover, we found that
respiratory-deficient muscle fibres were more likely to be
atrophic compared with respiratory-normal counterparts.
Conclusions: Our findings suggest that mitochondrial dys-
function has a role in sIBM progression. A strong correla-
tion between the severity of inflammation, degree of
mitochondrial changes and atrophy implicated existence
of a mechanistic link between these three parameters. We
propose a role for inflammatory cells in the initiation of
mitochondrial DNA damage, which when accumulated,
causes respiratory dysfunction, fibre atrophy and ulti-
mately degeneration of muscle fibres.
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Introduction
Sporadic inclusion body myositis (sIBM) is the most
common myopathy of older age, with onset typically after
the age of 50 years [1]. sIBM is categorized as one of
the idiopathic inflammatory myopathies along with
dermatomyositis, polymyositis and necrotizing autoim-
mune myositis [2]. However, in contrast to these other
disorders, there is no established role for immunosuppres-
sive treatment in the management of patients with sIBM.
This is likely to reflect the contribution of degenerative
mechanisms to the pathogenesis in addition to an abnor-
mal immune response.
In sIBM, there is a distinctive pattern of muscle involve-
ment which forms a core element of the clinical diagnosis
[3]. Muscle biopsy reveals a combination of excessive
inflammation (consisting mostly of CD8-positive T lym-
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phocytes) [4] with widespread upregulation of sarcol-
emmal and sarcoplasmic major histocompatibility
complex-I (MHC I) with degenerative features that include
abnormal sarcoplasmic protein aggregation and increased
mitochondrial impairment [5–7].
Mitochondrial abnormalities are very common in
muscles of sIBM patients and they include diminished res-
piratory chain function, abnormal proliferation and accu-
mulation of mitochondria [6]. In Oldfors and colleagues’
initial study of muscle biopsies from three sIBM patients,
there was low or absent cytochrome c oxidase (COX) activ-
ity, despite normal succinate dehydrogenase (SDH) activ-
ity, in 2–5% of all muscle fibres (deltoid muscle). Less than
1% of COX-deficient fibres were observed in age matched
controls, indicating that the mitochondrial histochemical
changes in sIBM were related to disease pathology and not
just a consequence of normal ageing. In situ hybridization
analysis of tissue sections provided evidence for the exist-
ence of mitochondrial DNA (mtDNA) deletions, which
was further confirmed with Southern blotting [6]. An
extended study of 20 additional sIBM patients demon-
strated the frequency of respiratory chain deficiency to
affect 0.5–5.0% of all fibres [8]. The potential importance
of the mitochondrial changes in sIBM is highlighted by the
fact that COX-deficient fibres are the most consistent
abnormal histopathological feature in muscle biopsies
from sIBM patients after MHC I upregulation, present in
98% of cases compared with 90% with rimmed vacuoles
or inclusions [9]. Molecular analysis of a number of indi-
vidual fibres revealed the presence of different large-scale
mtDNA deletions and only one point mutation, in a tRNA
gene. It is still unknown why mtDNA mutations accumu-
late in sIBM and what the consequence of the respiratory
deficiency is to the disease progression.
The aetiology of these changes in the muscle of patients
with sIBM is still unclear but there is growing evidence
that both inflammation and degeneration can play a role.
Findings from another autoimmune disease, multiple
sclerosis, showed abundant population of respiratory-
deficient neurones in patients’ brains [10]. Mitochondrial
injury in this disease may be triggered by reactive oxygen
(ROS) and nitric oxide species (RONS) generated by acti-
vated microglia and macrophages, which are frequently
found within multiple sclerosis lesions [11].
In this study we wished to examine the prevalence of
respiratory deficiency and its relationship to the inflam-
mation and atrophy in muscle biopsies from patients with
sIBM. We have investigated the cellular phenotype in
muscle tissue from 16 sIBM patients. We were interested
to establish whether the rate of the accumulation of the
mitochondrial defect in muscle tissue relates directly to the
clinical phenotype observed in these patients as well as
determining whether the severity of mitochondrial abnor-
malities, atrophy and inflammation could be indicative of
disease progression.
Methods
Patients and muscle biopsies
Open muscle biopsies obtained from 16 sIBM patients
were used in this study. All patients included in the study
had a diagnosis of clinically defined or pathologically
defined sIBM according to recent criteria [3]. Disease pro-
gression was estimated in 10 of 16 patients using serial
hand-held myometry (Citec) over a mean of 3.5 years
(range 2–7 years). Strength in Newtons was determined
for muscle groups in upper and lower limbs. Muscle
groups assessed included shoulder abduction, elbow
flexion and extension, wrist extension, pinch and grip, hip
flexion, hip abduction, knee extension and dorsiflexion.
The selection of muscle groups varied among patients
with a mean of seven groups assessed (range three to
eight) either unilaterally on the weaker side [4] or bilater-
ally [6]. Knee extension and grip strength were both deter-
mined in all but one patient. Measurements were
performed in standardized fashion by a trained physi-
otherapist. For each muscle group, at least two measure-
ments were performed to obtain values within 10%
variation and the mean of these two determined. Change
in strength was calculated as a percentage relative to
baseline.
All muscle biopsies were taken from vastus lateralis,
except for two biopsies which were taken from deltoid and
gastrocnemius, frozen in isopentane immersed in liquid
nitrogen and stored at −80°C. Clinical information about
the patients is summarized (Table S1). Ethical approval
was granted and consent for research was obtained from
all individuals taking part in the study.
Histological and immunohistochemical analyses
Frozen biopsies were cut at 10 μm and selected sections
were used for haematoxylin and eosin (H&E) staining
according to an established protocol. Other sections were
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used for sequential cytochrome c oxidase and succinate
dehydrogenase (COX/SDH) histochemistry in order to
detect respiratory-deficient fibres as previously described
[12]. Sections used for molecular analysis were cut
at 20 μm, mounted onto polyethylenenaphthalate
(PEN) slides (Leica Microsystems, Milton Keynes,
UK) and reacted for SDH activity only, as the 3,3′-
Diaminobenzidine (DAB) used in COX reaction solution
interferes with some downstream mtDNA analyses [13].
Serial sections were cut at 10 μm and dried at room
temperature for 1 h. The sections were fixed with 4% PFA
(Sigma, Gillingham, Dorset, UK) permeabilized in a gradi-
ent of methanol and endogenous peroxidase activity was
blocked by incubation with 0.3% hydrogen peroxide. Non-
specific protein interactions were quenched by incubation
with the blocking solution [5% bovine serum albumin/
Tris-buffered saline and Tween 20 (BSA/TBST)]. Primary
antibodies recognizing mitochondrial proteins (outer
mitochondrial membrane protein: anti-porin, matrix
protein: anti-PDH E2, complex I subunits: anti-cI-19 and
anti-cI-20, complex IV subunits: anti-COX-I and anti-
COX-IV, complex II subunit: cII-70) and inflammatory
cells (lymphocytes: anti-CD3 and macrophages: anti-
CD68) were diluted to optimal concentrations in the
blocking solution (Table S2). The antibodies were applied
onto the section for an overnight incubation at +4°C. All
of the antibodies detecting mitochondrial proteins were
purchased from Abcam (Cambridge, UK) and both CD3
and CD68 antibodies were acquired from DAKO (Ely, UK).
The following day, slides were washed in TBST and the
tissue sections incubated with mitochondrial complexes
antibodies were then incubated with the universal probe
followed by polymer-horseradish peroxidase (HRP)
according to manufacturer’s instructions (X-Cell plus
Polymer HRP detection kit, MenaPath, A. Menarini Diag-
nostics). Sections which had been immune-reacted with
anti-CD3 and anti-CD68 antibodies were incubated with
secondary anti-mouse biotinylated antibody (Vector Labo-
ratories, California, USA) for 1.5 h at room temperature,
then washed and incubated with ABC peroxidase complex
for 30 min (Vector Laboratories). Signal was developed
with DAB chromogen solution (SigmaFast tablets, Sigma)
and the sections were counter-stained with Mayer’s
Haematoxylin. Slides were dehydrated, cleared in Histo-
Clear II (National Diagnostics, Atlanta, GA, USA) and
mounted in DPX mounting medium (Sigma). Images of
serial sections were obtained using Zeiss Axio Vision
microscope (Carl Zeiss, Oberkochen, Germany).
Serial tissue sections – experimental set-up
Serial sections were stained in a fixed order to ensure
robust and comparable analyses between the patients
(Figure 1). Individual muscle fibres were traced in all sec-
tions and their characteristics reported. Sequential COX/
SDH histochemistry was undertaken on the first and last
section of the series to verify whether an individual muscle
fibre had the same biochemical phenotype throughout the
analysed length (Figure 1). Complete analysis was only
possible on 13 biopsies because in the remaining three
biopsies one or more of sections from a series failed to
produce a reliable antibody labelling or the muscle mor-
phology was affected by freezing or storage procedure. It is
worth noting that although patient 11 and 13 had biop-
sies taken from deltoid or gastrocnemius respectively
rather than quadriceps muscle (Table S1), neither of them
presented unusual results following histochemical and
immunohistochemical analyses.
Real-time PCR analysis of DNA extracted from
single cells
Frozen muscle sections (20 μm), mounted on PEN slides
and reacted for SDH activity, were used for mtDNA analy-
ses. Single muscle fibres of interest were dissected out
using Leica Laser Microdissection System (AS-LMD) or
PALM MicroBeam (Carl Zeiss). The cells were then lysed as
previously described [14]. Analysis of deletion levels in
mtDNA were carried out using multiplex real-time PCR
assay to detect two mitochondrial genes, MT-ND1 and
MT-ND4 according to a previously optimized protocol
[15,16].
Whole mitochondrial genome cycle sequencing
The method to determine the sequence of the entire
mitochondrial has been described elsewhere [17]. This
was determined in five individual muscle fibres from one
patient (patient 7). Sequencing results were compared
with the revised Cambridge sequence [18,19].
Counting of fibres and inflammatory cells
The proportion of respiratory-deficient cells (COX-
deficient) and complex I subunit 19-deficient cells (cI-19-
deficient) was presented as a percentage of a total number
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Figure 1. Overview of the experimental set-up for the assessment of serial muscle sections from inclusion body myositis muscle biopsies.
The scale bars measure 100 μm.
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of fibres counted (n = 150 ± 15). Atrophy level was
assessed by counting approximately 500 (n = 500 ± 55)
fibres in each muscle biopsy. Only fibres with the smallest
diameter of less than 30 μm were considered atrophic and
were included in calculations. A larger number of fibres
were counted for the muscle atrophy analysis than the
COX/SDH analysis given COX-deficient fibres were more
frequent and distributed in a mosaic pattern whereas
atrophic fibres less common and sometimes unevenly dis-
tributed. For both the COX deficiency and atrophy counts,
randomly selected areas were chosen for assessment,
which was carried out using a stereological system (Stereo
Investigator, MBF Bioscience, Williston, VT, USA). Inflam-
matory cells were rarely evenly distributed within the
muscle tissue therefore in order to quantify abundance of
T lymphocytes (CD3-positive) and macrophages (CD68-
positive) a representative area was selected for each case.
The representative area (0.7–2.5 mm2) reflected inflam-
matory status of the entire muscle section. Results were
presented as a number of either T cells or macrophages per
mm2 of tissue.
Each of these counts was carried out independently
with no knowledge of the previous results. The counts
were verified by an independent investigator in three ran-
domly chosen cases and the difference in results obtained
by the two independent investigators did not exceed 10%.
This discrepancy may have been caused by a different
region of the biopsy analysed by the second investigator.
Statistical analysis
Statistical analyses of the data were carried out using
MiniTab 16. Normally distributed data were analysed with
T-tests and nonparametric data with appropriate
nonparametric tests including Mann–Whitney and
Wilcoxon signed rank test. The difference between data
sets was considered statistically significant only when P
was equal or lower than 0.05. When data were analysed
using multiple tests P was adjusted accordingly.
Results
Muscle fibres containing mitochondrial
abnormalities are common in sIBM patients
In agreement with reports from other groups [6], we con-
firmed presence of muscle fibres with evidence of
mitochondrial dysfunction in vastus lateralis, deltoid or gas-
trocnemius biopsies obtained from 16 sIBM patients (Table
S1). Using COX/SDH histochemistry we distinguished two
populations of fibres bearing mitochondrial defects – cells
without any detectable COX activity (COX-deficient fibres)
(Figure 2a) and cells with markedly reduced levels of this
enzyme (COX-intermediate fibres) (Figure 2b) [13]. Subse-
quently, we labelled serial muscle biopsy sections with a
range of antibodies detecting different protein compo-
nents of the mitochondrial respiratory chain (Figure 3a).
Figure 2. The demonstration of muscle fibres with impaired mitochondrial respiration in sIBM biopsies demonstrated by combined
COX/SDH histochemistry and COX histochemistry alone. The muscle biopsy sections shown are from patient 10. (a) Entirely COX-deficient
fibres (no COX activity detected with COX histochemistry alone; fibre 1) and (b) intermediate fibres (reduced COX activity; fibre 2) were found
in every sIBM biopsy. Scale bar is 100 μm for all images.
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Figure 3. Characterization of the mitochondrial respiratory phenotype in muscle fibres from sIBM muscle biopsies. (a) Selected components
of mitochondrial respiratory chain were detected by immunohistochemistry (IHC) and COX/SDH histochemistry. Analyses were performed
on transverse serial sections (asterisks depict a single muscle fibre in sequential cryosections). Four categories of fibres were identified: fully
respiratory-deficient (COX-deficient), partially respiratory-deficient (COX-intermediate), lacking complex I expression (cI-deficient) and
respiratory normal (COX-normal). COX/SDH histochemistry was carried out on the first and the last of serial sections to confirm the same
phenotype. Porin or PDH E2 (dihydrolipoamide transacetylase of pyruvate dehydrogenase) were used as indicators of mitochondrial mass.
Images were acquired at 20× magnification, the scale bar displayed in the first image measures 50 μm and applies to all images in this panel.
(b) Summary of phenotype of three groups of abnormal fibres in sIBM. ‘−’ signifies lack of enzyme activity or protein expression, ‘+’ normal
activity of expression, ‘+/−’ presence or absence of protein, reduced enzymatic activity. (c) Percentage of each of the three groups of
pathological fibres in biopsies from 13 sIBM patients. (d) Histochemistry and IHC carried out on a biopsy from patient 7 who showed the
highest deficiency levels in COX activity and components of mitochondrial complexes. The scale bars measure 100 μm.
Mitochondrial pathology of sIBM 293
NAN 2015; 41: 288–303© 2014 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Cells entirely lacking COX activity expressed neither
complex I subunits: cI-19 and cI-20 nor mitochondrially
encoded subunit I of complex IV (COX-I) and had either
preserved or reduced expression of nuclear encoded
subunit IV of complex IV (COX-IV). Similarly, we failed to
detect expression of either of the two subunits of complex
I in COX-intermediate fibres. These fibres, however, had
preserved expression of COX-I. Most intriguingly, we dis-
tinguished a group of fibres with normal COX activity
and complex IV protein level but entirely abolished
expression of complex I subunits. These data lead to for-
mulation of three categories of abnormal muscle fibres
found in sIBM biopsies: COX-deficient, COX-intermediate
and complex I-deficient (Figure 3b). All three groups
of aforementioned fibres showed high levels of both
complex II and porin expression implicating that reported
changes in expression of complex I and IV were not a
consequence of a low mitochondrial density within
the cells. Proportion of each of the three groups of
abnormal muscle fibres in individual biopsies from sIBM
patients is presented (Figure 3c). The biopsy from patient
7, which demonstrated a particularly high level of COX-
deficient and COX-intermediate fibres, is also presented
(Figure 3d).
Respiratory deficiency was not restricted to one fibre
type. Both slow (Type I) and fast (Type II) twitch fibres
encompassed a portion of fibres with defective oxidative
phosphorylation as assessed on the basis of COX inactivity
(Figure 4a).
Investigating the degree of respiratory deficiency
in muscle biopsies from patients with sIBM
Quantitative analysis of COX/SDH histochemistry
revealed that the combined proportion of COX-deficient
and COX-intermediate fibres varied between 1.5% and
79.1% of affected fibres. Complex I-deficient fibres consti-
tuted between 1.7% and 88.7% of total fibres counted
and, more importantly, in the great majority of biopsies
complex I-deficient fibres were more abundant than COX-
deficient cells (Figure 4b). Statistical analysis of all cases
showed that complex I-deficient fibres were more abun-
dant than COX-deficient fibres in the analysed cohort of
patients (Wilcoxon signed rank test, P = 0.002). Levels of
neither COX deficiency nor complex I deficiency correlated
with the age of disease onset (r = −0.39, P = 0.02704
and r = −0.48, P = 0.1611 respectively). Additionally,
strength decline, measured by myometry, failed to corre-
late with either COX deficiency (r = 0.11, P = 0.7614) or
complex I deficiency (r = 0.24, P = 0.5020).
Respiratory deficiency is caused by mtDNA
deletions in a proportion of abnormal
muscle fibres
We used multiplex real-time PCR assay to investigate
whether fibres expressing a respiratory-deficient pheno-
type carried high levels of mtDNA deletions as previously
reported [8]. Analysis was carried out on DNA extracted
from single muscle fibres from eight patients and data
were collected from 190 COX-deficient and 62 COX-
normal fibres. As expected, the overwhelming majority
(95%) of COX-normal cells contained a very low level of
mtDNA deletion (Figure 5a). COX-deficient cells could be
grouped into three categories based on their deletion
content. Muscle fibres with a ‘high deletion load’ (60–
99%) were the most abundant group and comprised 51%
of respiratory-deficient fibres, ‘medium deletion load’
group (30–59%), encompassed only 4% of cells and ‘no
deletion’ group was represented by 45% fibres (Figure 5a).
The difference in MT-ND4 deletion load between COX-
normal and COX-deficient group was highly statistically
significant (Figure 5a, Mann–Whitney test, P < 0.0001).
We noted high level of variability between individual
patients. We measured mtDNA deletion levels in eight
individual cases in between 14 and 45 COX-deficient
muscle fibres per case (Figure 5b). Most patients showed a
wide distribution in mtDNA deletion load in individual
fibres from the COX-deficient group. Patient 7 is an outlier
and the particularly high level of COX deficiency in this
patient’s muscle is currently difficult to explain. Majority
of single cells as well as the homogenate analysis have not
revealed mtDNA deletion using our MT-ND1/MT-ND4
assay. We have also sequenced the entire mitochondrial
genome from five COX-deficient cells from this patient but
did not detect any pathogenic mtDNA point mutations.
Multiple mtDNA deletions were clearly detected by long
range PCR protocols (not shown). We believe there are
several potential explanations. There could be mtDNA
deletions that either do not encompass the MT-ND4 region
or stretch over both MT-ND1 and MT-ND4 hence they are
not detectable with our real-time assay. Alternatively,
COX-deficient fibres may have a mixed genetic aetiology
and in some of them the observed respiratory defect may
be unrelated to mtDNA. The analysis of homogenate DNA
did not show a significant level of mtDNA deletion in any
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Figure 4. Immunohistochemistry for myosin heavy chain slow and fast (MHCs and MHCf respectively) and contribution of
respiratory-deficient and complex I-deficient fibres to the total number of fibres in biopsies. (a) Fibres depicted with numbers demonstrate
that both slow and fast twitch fibres are affected by mitochondrial deficiency. There are some fibres that co-express both MHC isoforms
(marked with green asterisks). (b) Percentage of COX-deficient (green bars) and complex I-deficient (blue bars) of the entire fibre population.
On average 150 fibres were counted in each biopsy, 16 sIBM cases were analysed. Group of muscle fibres with deficient complex I (complex
I-deficient) was statistically more abundant than COX-deficient (Wilcoxon signed rank test, P = 0.002). The scale bar corresponds to 100 μm
and applies to all images.
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Figure 5. mtDNA deletion load detected in single muscle fibres as well as muscle homogenates from eight sIBM patients. (a) Combined
single fibre mtDNA deletion data from all eight cases were plotted to demonstrate difference between the entire COX deficient (190 cells) and
COX normal (62 cells) muscle fibre population. Horizontal lines indicate the median. The difference in deletion load between COX-deficient
and COX-normal cells was statistically significant (Mann–Whitney test, P < 0.0001). Each dot signifies a reading from one cell. (b) mtDNA
deletion levels from individual respiratory-deficient cells were plotted for each patient to indicate variability between patients. (c) mtDNA
deletion load in muscle homogenate DNA from the same eight sIBM patients. (d) individual muscle fibres of one of the four categories:
COX-deficient (54 cells), COX-intermediate (20 cells), complex I-deficient (10 cells) and COX normal (40 cells). The cells were characterized
based on histochemistry for COX/SDH activity and IHC for selected mitochondrial respiratory chain components. Horizontal lines indicate
the median. Statistically significant difference was only achieved for COX-deficient vs. COX-normal (**P = 0.0003) and COX-intermediate and
vs. COX-normal groups (*P = 0.0135) (Mann–Whitney test).
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of the patients. Two patients had approximately 20% of
mtDNA heteroplasmy; however, this is below the sensitiv-
ity of this assay [15,16].
An interesting trend was observed in the level of
mtDNA deletion (% mtDNA heteroplasmy) in four groups
of previously characterized fibres: COX-deficient, COX-
intermediate, complex I-deficient and COX-normal. As
expected, the highest mutation load was found in COX-
deficient fibres with median of 23.3%, then gradually
lower in the remaining three groups (median of 9.4, 1.6
and 0 for intermediate, complex I deficient and COX-
normal groups respectively). These differences, however,
reached statistical significance only for COX-normal vs.
COX-deficient cells (Mann–Whitney test, P = 0.0003) and
COX-normal vs. COX-intermediate (P = 0.0135). The test
performed was corrected for multiple testing and accept-
able statistical confidence level was brought down to 2.5%
(P of 0.025). There were cells, in all groups, which did not
contain any detectable mtDNA deletions (Figure 5c).
Inflammatory infiltrate correlates with number
of respiratory-deficient fibres in sIBM muscle
We investigated the inflammatory status of the sIBM
muscle biopsies in relation to the levels of respiratory defi-
ciency using immunohistochemical labelling for two anti-
gens: CD3 and CD68 in order to identify populations of T
lymphocytes and macrophages respectively (Figure 6a).
Consistent with findings from other groups, the CD3-
positive population was more abundantly represented
than the CD68-positive group [20]. We found a significant
relationship between the number of fibres with
mitochondrial abnormalities and immune cells residing
within the tissue (Figure 6b); stronger for CD3-positive T
cells (r = 0.66, P = 0.007) than macrophages (r = 0.24,
P = 0.04). Although spatial association between immune
cells and respiratory-deficient fibres was only occasionally
observed in the tissue, positive correlation between the
total amount of inflammation and the degree of
mitochondrial damage would strongly suggest a causative
link between them (Figure 6).
Relationship between COX deficiency and
atrophy in sIBM muscle
A cardinal clinical feature of sIBM is muscle wasting, a
consequence of degeneration of muscle fibres, and there-
fore we investigated atrophy in the sIBM biopsies
(Figure 7a). According to commonly accepted criteria
atrophic fibres were those which smallest diameter meas-
ured less than 30 μm [21]. Analysis of average percentage
of COX-deficient and COX-normal atrophic fibres in the
entire atrophic population clearly shows that COX-
deficient fibres dominate over COX-normal fibres (one-
sample T-test, P = 0.009) (Figure 7b). We also compared
the proportion of atrophic fibres in the COX-deficient and
COX-normal populations in individual sIBM cases (10
cases). We found that in all of the biopsies examined, the
percentage of COX-deficient atrophic fibres in the total
COX-deficient population was markedly higher than that
of COX-normal atrophic fibres in the overall COX-normal
population (paired T-test, P < 0.0001). This would suggest
that COX-deficient cells are more prone to degeneration
than COX-normal fibres (Figure 7c). Images of COX and
SDH activity in a representative biopsy from patient 7
show the degree of atrophy in the respiratory normal and
deficient subpopulations of muscle cells (Figure 7d).
Discussion
Mitochondrial dysfunction is common and often very
prominent in muscle from sIBM patients. We demonstrate
that there are abnormalities in the expression of indi-
vidual mitochondrial respiratory complexes, and propose
that a protocol combining mitochondrial respiratory
subunit expression and COX/SDH activity provides a
clearer picture of the mitochondrial changes in sIBM. We
have explored the nature of the mitochondrial defect in
individual muscle fibres and, in accordance with previous
reports, we show that some of them accumulate high level
of clonally expanded mtDNA deletions. We also show that
respiratory-deficient fibres are more prone to atrophy indi-
cating that the mitochondrial defect has a direct effect on
muscle wasting. In addition, there is a clear correlation
between the overall percentage of respiratory-deficient
fibres and the degree of T lymphocyte infiltrate. Thus there
seems to be a direct link between the inflammation present
in muscle environment and the mitochondrial defect.
Combining COX/SDH histochemistry with immunohis-
tochemical analysis of protein levels of selected
mitochondrial respiratory chain components, we charac-
terized three distinct groups of cells with mitochondrial
abnormalities. Fibres with isolated complex I deficiency
present the least severe phenotype. COX-intermediate
fibres show reduced COX activity with relatively preserved
COX-I protein, but loss of complex I. Finally, COX-deficient
Mitochondrial pathology of sIBM 297
NAN 2015; 41: 288–303© 2014 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Figure 6. Correlation between severity of immune infiltration and number of respiratory-deficient fibres in sIBM tissue. (a) Serial muscle
sections from two patients showing COX/SDH combined histochemistry, T lymphocytes (CD3) and macrophages (CD68). Pink asterisks
depict COX-deficient and COX-intermediate fibres throughout the sections; only some appear to be spatially associated with immune cells.
(b) Graphs showing numbers of T cells (dark green bars) and macrophages (light green bars) counted in a representative area of each
biopsy. There is a correlation between the number of invading CD3-positive cells and COX-deficient muscle fibres with the P of 0.007 and, a
less strong correlation, between CD68-positive cells and COX-deficient fibres with P of 0.04 (fitted line plot). The scale bars measure 100 μm.
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Figure 7. Atrophy in sIBM muscle sections. (a) H&E stained biopsy sections from two patients showing great variety in size of individual
muscle fibres. (b) Average percentages of atrophic COX-normal and COX-deficient in the whole atrophic population measured in 11 cases.
Statistically significant difference was reached between COX-deficient and COX-normal groups (*P = 0.009, one-sample T-test).
(c) Percentages of atrophic cells in COX-deficient and COX-normal populations in 11 individual patients. The difference between contribution
of COX-deficient atrophic cells and COX-normal counterparts in the overall COX-deficient and COX-normal groups respectively was highly
significant (P < 0.0001, paired T-test). (d) COX/SDH histochemistry carried out on a biopsy from patient 7, which demonstrates high
contribution of atrophic respiratory-deficient fibres to the entire COX-deficient cell population (‘COX/SDH’ signifies first section in the series
and ‘COX/SDH end’ the last section). The scale bars measure 100 μm.
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cells have lost complex I and IV protein expression as well
as COX enzymatic activity. This suggests a progressive
nature of mitochondrial dysfunction which begins with
complex I downregulation. We believe that by determin-
ing protein levels of complex I in sIBM muscle biopsies we
are able to detect mitochondrial changes at the earliest
stage of the disease. Therefore we postulate that the loss of
complex I protein subunits, rather than COX activity,
serves as a more sensitive marker of mtDNA damage in
muscle from patients with sIBM. In our cohort of 16
patients we did not see a clear correlation between the
number of COX-deficient or complex I-deficient and sever-
ity of disease progression. This finding does not dismiss a
possibility that such correlation would be observed in
a larger study. We believe that a combined approach
of COX/SDH histochemistry and respiratory chain
immunohistochemistry is valuable in understanding
basic biology of mtDNA damage accumulation and its
consequence on the muscle, although as yet its use in
clinical practice is uncertain.
Consistent with a previous report from Oldfors et al. we
found clonally expanded mtDNA deletions in COX-
deficient fibres [6]. Significant increase in a proportion of
respiratory-deficient muscle fibres, above the level pre-
dicted by normal ageing, is unique to sIBM and not
observed in other inflammatory myopathies including
polymyositis and dermatomyositis [22]. Interestingly, not
all of the respiratory-deficient single fibres had detectable
level of deletion using our real-time PCR assay. This
finding is entirely compatible with results previously
obtained by our laboratory studying patients with multi-
ple mtDNA deletions due to nuclear gene disorders affect-
ing mtDNA maintenance and in normal ageing [15,16]. It
is possible that deletions in these fibres remove a fragment
of mtDNA which does not contain MT-ND4 region and
thus they are not detected by the real-time PCR assay we
performed. The assay will also not detect a deletion which
encompasses both MT-ND4 and MT-ND1. A detailed
analysis of mtDNA copy number excluded mtDNA deple-
tion as the cause of respiratory deficiency in these cells.
Finally, it is also possible that a clonally expanded point
mutation is causing respiratory deficiency; a tRNA point
mutation present at a very high level in a muscle fibre from
a sIBM patient was previously reported [23]. However, this
does not explain all the findings in our patients as
sequencing analysis of the entire mitochondrial genome,
from five single COX-deficient cells, failed to detect any
pathogenic point mutations.
We also investigated immune infiltrate and its poten-
tial relationship with respiratory defect in muscle fibres.
Interestingly, a strong correlation exists between the
severity of immune cell invasion and the number of
fibres with mitochondrial abnormalities. We assessed the
size of CD3-positive population, which is an overall pool
of T lymphocytes combining all subtypes including
cytotoxic, helper, memory and regulatory T cells. A
number of studies describe cytotoxic CD8-positive T cells
as a dominant group of lymphocytes in sIBM muscle
tissue. FOXP3-positive regulatory T cells have recently
been reported to reside in muscles from inflammatory
myopathies including sIBM and, interestingly, their
number is proportional to the number of cytotoxic T cells
[24]. In order for the mtDNA mutation to accumulate to
the level of detection the muscle fibre must be spared
from T cell mediated lysis which can only be granted by
regulatory T cells. Scarcity of fibre necrosis as opposed to
fibre atrophy in sIBM is supportive of this notion. It is
intriguing why mtDNA damage has not been reported in
other inflammatory myopathies. COX-deficient fibres are
occasionally found in dermatomyositis; however, these
are believed to arise as a consequence of ischemia, based
on their location associated with blood vessels [25]. We
speculate that the long-term inflammatory environment
in sIBM must be important. It is worth pointing out that
although we rarely saw a colocalization of immune cells
with respiratory-deficient muscle fibres in sIBM sections,
it does not exclude a potential immune-mediated mtDNA
damage. The mtDNA rearrangements we identified in
COX-deficient fibres had clonally expanded over a period
of many years and the inflammatory cells responsible for
the initial insult had time to move away from the area
[26]. Therefore the degree of inflammation likely repre-
sents the amount of damage inflicted overall which is
then followed by the clonal expansion event. It is also
worth noting that an increase in COX-deficient muscle
fibres has been reported in patients with multiple sclero-
sis, another chronic inflammatory condition [10].
A question remains as to whether accumulation of
mtDNA mutation has any phenotypic effect on muscle
fibres. This study has shown that respiratory-deficient
fibres were more prone to atrophy than fibres with normal
respiration. This observation is strongly supported by data
from studies investigating the effects of respiratory defi-
ciency in ageing muscle [27,28], although, in our experi-
ence as a diagnostic centre, we do not see a significant
amount of atrophy in respiratory-deficient fibre pool in
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patients with primary mtDNA mutations. If atrophy is
indeed caused by mitochondrial deficiency in sIBM, and it
is an irreversible process ultimately leading from gradual
size reduction to degeneration of a fibre, then the contri-
bution of mitochondrial involvement to the muscle
wasting is important.
This study adds new information to the role of mito-
chondria in sIBM but many challenges remain. Our study
was necessarily limited by the number of patients avail-
able, the lack of longitudinal data, counting based on a
limited number of fibres and the patchy nature of the
inflammatory involvement in inclusion body myositis
meaning we could only study representative areas.
Perhaps the most important challenge remains is mecha-
nism by which the inflammation leads to the
mitochondrial defect. We hypothesize a link involving
cross-talk between inflammation, mtDNA rearrangement
accumulation and atrophy in sIBM (Figure S1). Once
established these defects will inevitably progress, which
may explain the lack of clinical benefit from immunosup-
pression in patients who typically present with a prolong
duration of their disease. Whether very early intervention
would limit the mitochondrial involvement is not known.
Finally, we see remarkable variation in the degree of
mitochondrial involvement between patients and we are
uncertain whether this reflects different pathogenic
mechanisms or the sensitivity of the mitochondrial
genome to mutate in some patients. A greater understand-
ing of these disease mechanisms may lead to new thera-
peutic avenues for patients with this progressive muscle
disease.
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Supporting information
Additional Supporting Information may be found in
the online version of this article at the publisher’s
web-site:
Figure S1. We hypothesize that the long-term inflamma-
tion in sIBM is a key trigger to the mtDNA damage,
leading to the accumulation of clonally expanded
mtDNA deletions. Mitochondrial DNA mutations may
form as a result of inflammatory insult such as RONS
(reactive oxygen and nitrogen species) or inflammatory
cytokines present in the environment. Mitochondrial
mutations accumulated above a critical threshold can
cause a phenotypic effect such as muscle atrophy, split-
ting and breakage (Bua et al. 2002), explaining the cor-
relation of respiratory deficiency with muscle atrophy. As
sIBM is considered an autoimmune disease we may
speculate that an initial viral infection triggers breakage
of immune tolerance mediated by CD8-positive T cells
and causes an autoimmune response. Secretion of
inflammatory cytokines results in upregulation of MHC I
and the co-stimulatory molecules by muscle fibres, which
then become a target for an immune attack. The inflam-
matory environment may directly cause double-strand
breaks in mtDNA (dsDNA breaks). Alternatively, MHC I
upregulation may cause ER stress response which leads
to accumulation of misfolded toxic proteins such as
β-amyloid. The latter augments inflammatory reaction
and associates with mitochondrial membranes disrupt-
ing intramitochondrial processes. Faulty repair mecha-
nisms subsequently lead to the accumulation of
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damaged mtDNA molecules in the cell causing respira-
tory deficiency (Krishnan et al. 2008).
Table S1. Clinical data of cases analysed in the study.
Table S2. Description and source of the antibodies used for
IHC assessments.
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